腹腔镜肝切除术治疗原发性肝癌患者应用氢吗啡酮联合纳布啡静脉自控镇痛控制疼痛作用研究*

doi:10.3969/j.issn.1672-5069.2022.03.028

摘要/Abstract

摘要： 目的探讨腹腔镜肝切除术(LH)治疗原发性肝癌(PLC)患者应用氢吗啡酮联合纳布啡静脉自控镇痛(PCIA)控制疼痛的效果。方法 2018年1月～2021年1月我院收治的PLC患者104例,随机分为对照组52例和观察组52例,两组患者均接受LH手术,在对照组,给予舒芬太尼联合纳布啡用于术后PCIA,而在观察组给予氢吗啡酮联合纳布啡用于术后PICA。采用疼痛视觉模拟评分(VAS)评价术后疼痛程度,使用流式细胞仪检测外周血T细胞亚群CD3⁺细胞、CD4⁺细胞、CD8⁺细胞和NK细胞百分比。结果在术后24 h,观察组静态VAS和动态VAS分别为(2.5±0.8)分和(3.7±1.2)分,显著低于对照组【分别为(4.3±1.2)分和(5.8±1.7),P＜0.05】,在术后72 h,静态VAS和动态VAS分别为(1.1±0.4)分和(3.2±0.9)分,显著低于对照组【分别为(2.6±0.7)分和(5.1±1.3),P＜0.05】;术后,两组肝功能指标变化无显著性差异(P＞0.05);在术后7 d,观察组外周血CD3⁺细胞、CD4⁺细胞、CD8⁺细胞和NK细胞百分比分别为(76.3±7.5)%、(36.8±4.9)%、(32.5±3.2)%和(16.3±2.9)%,与对照组【分别为(75.2±7.4)%、(37.6±4.4)%、(31.2±3.4)%和(17.4±2.6)%】比,差异无统计学意义(P＞0.05)。结论氢吗啡酮联合纳布啡用于LH后PCIA能够有效减轻患者疼痛程度。

关键词: 原发性肝癌, 腹腔镜肝癌切除术, 静脉自控镇痛, 氢吗啡酮, 纳布啡

Abstract: Objective The aim of this study was to investigate pain control by hydromorphone and nalbuphine combination for patient-controlled intravenous analgesia (PCIA) in patients with primary liver cancer (PLC) undergoing laparoscopic hepatectomy (LH). Methods 104 patients with PLC were encountered in our hospital between January 2018 and January 2021, and they were randomly divided into control (n=52) and observation group (n=52). All patients with PLC underwent LH, and the sufentanil and nalbuphine in patients in the control, while the hydromorphone and nalbuphine in patients in the observation for postoperative PCIA were applied. The T cell subsets, such as CD3⁺ cells, CD4⁺cells, CD8⁺ cells and NK cells, were detected by flow cytometry. The postoperative pain was assessed by visual analogue scale (VAS). Results At 24 h after surgery, the static and dynamic VAS scores in observation group were (2.5±0.8) points and (3.7±1.2) points, significantly lower than [(4.3±1.2) points and (5.8±1.7) points, P<0.05] in the control; at 72 h after surgery, the static and dynamic VAS scores in the observation group were (1.1±0.4) points and (3.2±0.9) points, significantly lower than [(2.6±0.7) points and (5.1±1.3) points, P<0.05] in the control; after surgery, there were no significant differences as respect to common liver function tests (P>0.05); at 7 d after surgery, the percentages of CD3⁺ cells, CD4⁺cells, CD8⁺ cells and NK cells in the observation group were (76.3±7.5)%,(36.8±4.9)%,(32.5±3.2)% and(16.3±2.9)%, all not significantly different as compared to [(75.2±7.4)%,(37.6±4.4)%,(31.2±3.4)% and (17.4±2.6)%] in the control (P>0.05). Conclusion The application of hydromorphone and nalbuphine combination in patients with PLC for PCIA after LH could effectively alleviate pain.

Key words: Hepatoma, Laparoscopic hepatectomy, Patient-controlled intravenous analgesia, Hydromorphone, Nalbuphine

孙浩, 曹丽, 曹林, 龙云. 腹腔镜肝切除术治疗原发性肝癌患者应用氢吗啡酮联合纳布啡静脉自控镇痛控制疼痛作用研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 415-418.

Sun Hao, Cao Li, Cao Lin, et al. hydromorphone and nalbuphine combination for patient-controlled intravenous analgesia in patients with primary liver cancer undergoing laparoscopic hepatectomy[J]. Journal of Practical Hepatology, 2022, 25(3): 415-418.

参考文献

[1] Polidoro MA, Mikulak J, Cazzetta V, et al. Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells. World J Gastroenterol, 2020,26(33):4900-4918.
[2] Yang WS, Zeng XF, Liu ZN, et al. Diet and liver cancer risk: a narrative review of epidemiological evidence. Br JNutr, 2020,124(3):330-340.
[3] Shi JF, Cao M, Wang Y, et al. Is it possible to halve the incidence of liver cancer in China by 2050? Int J Cancer, 2021,148(5):1051-1065.
[4] Delvecchio A, Conticchio M, Ratti F, et al. Laparoscopic major hepatectomy for hepatocellular carcinoma in elderly patients: a multicentric propensity score based analysis. Surg Endosc, 2021,35(7):3642-3652.
[5] 吴丹,夏燕飞,杨晓明,等. 急性疼痛管理在胸科手术中镇痛的效果评价. 中华医学杂志,2020,100(38):3010-3013.
[6] Sato N, Satomi E, Yoshida T, et al. Hydromorphone incancer patients-a retrospective study. Gan To Kagaku Ryoho, 2020,47(12):1687-1690.
[7] 李涛,高晨,柴小青,等. 纳布啡PCIA对肝癌切除术患者术后细胞免疫功能的影响. 中华麻醉学杂志,2019,39(11):1357-1359.
[8] 中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,等. 原发性肝癌规范化病理诊断指南(2015年版).中华肝胆外科杂志,2015,21(3):145-151.
[9] Rosas S,Paço M, Lemos C, et al. Comparison between the visual analog scale and the numerical rating scale in the perception of esthetics and pain. Int Orthod,2017,15(4):543-560.
[10] Sharma R. Descriptive epidemiology of incidence and mortality of primary liver cancer in 185 countries: evidence from GLOBOCAN 2018.Jpn J Clin Oncol, 2020,50(12):1370-1379.
[11] Yang WS, Zeng XF, Liu ZN, et al. Diet and liver cancer risk: a narrative review of epidemiological evidence. Br JNutr, 2020,124(3):330-340.
[12] Yoshida H,Taniai N, Yoshioka M, et al. Current status of laparoscopic hepatectomy. J Nippon Med Sch,2019,86(4):201-206.
[13] Egger ME,Gottumukkala V, Wilks JA, et al. Anesthetic and operative considerations for laparoscopic liver resection. Surgery,2017,161(5):1191-1202.
[14] Katz P,Takyar S, Palmer P, et al. Sublingual, transdermal and intravenous patient-controlled analgesia for acute post-operative pain: systematic literature review and mixed treatment comparison. Curr Med Res Opin, 2017,33(5):899-910.
[15] Han L, Su Y,Xiong H, et al. Oxycodone versus sufentanil in adult patient-controlled intravenous analgesia after abdominal surgery: A prospective, randomized, double-blinded, multiple-center clinical trial. Medicine (Baltimore),201,97(31):11552-11565.
[16] Rakowski JA, Holloway RW, Ahmad S, et al. A prospective randomized trial of intravenous ketorolac vs. acetaminophen administered with opioid patient-controlled analgesia in gynecologic surgery.Gynecol Oncol,2019,155(3):468-472.
[17] Zhang Y, Zhang R, Ding N. Investigation of analgesic dose of nalbuphine combined with remifentanil after radical gastrectomy.Exp Ther Med, 2019,18(3):1633-1638.
[18] Raghav R, Jain R, Dhawan A, et al. Chronic co-administration of nalbuphine attenuates the development of opioid dependence.Pharmacol Biochem Behav,2018,175(1):130-138.
[19] Lee W, Gao X, Tang J,et al. Postoperative sufentanil intravenous patient-controlled analgesia within the first 24 hours: a retrospective study. Ann Palliat Med,2020,9(6):3932-3937.
[20] Sridharan K, Sivaramakrishnan G. Comparison of fentanyl, remifentanil, sufentanil and alfentanil in combination with propofol for general anesthesia: a systematic review and meta-analysis of randomized controlled Trials. Curr Clin Pharmacol,2019,14(2):116-124.
[21] Riba P, Tóth Z, Hosztafi S, et al. Effects of structural modifications of N-CPM-normorphine derivatives on agonist and antagonist activities in isolated organs. Acta Biol Hung,2019,54(2):177-181.
[22] Rodrigues S, Shin D, Conway M, et al. Hydromorphone versus morphine: a historical cohort study to evaluate the quality of postoperative analgesia. Can J Anaesth,2021,68(2):226-234.
[23] 范倩倩,计根林,聂煌,等. 氢吗啡酮联合纳布啡用于胃肠道手术后PCIA的效果. 中华麻醉学杂志,2020,40(12):1471-1474.
[24] Robles-Diaz M, Garcia-Cortes M, Medina-Caliz I, et al. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity. Liver Int,2015,35(11):2474-2482.
[25] Sung PS, Jang JW. Naturalkiller cell dysfunction in hepatocellular carcinoma: pathogenesis and clinical implications. Int J Mol Sci,2018,19(11):3648-3652.
[26] Garnelo M, Tan A, Her Z, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut, 2017,66(2):342-351.
[27] Zheng B, Wang D, Qiu X, et al. Trajectory and functional analysis of PD-1 high CD4⁺CD8⁺ T cells in hepatocellular carcinoma by single-cell cytometry and transcriptome sequencing. Adv Sci (Weinh),2020,7(13):20224-20236.
[28] Ma B, Liu X, Yu Z. The effect of high intensity focused ultrasound on the treatment of liver cancer and patients' immunity. Cancer Biomark,2019,24(1):85-90.
[29] 李涛, 高晨, 柴小青,等. 纳布啡PCIA对肝癌切除术患者术后细胞免疫功能的影响.中华麻醉学杂志,2019,39(11):1357-1359.
[30] Berkowitz BA,Ceretta KV, Spector S. Influence of active and passive immunity on the disposition of dihydromorphine-H3. Life Sci,2017,15(5):1017-28.

腹腔镜肝切除术治疗原发性肝癌患者应用氢吗啡酮联合纳布啡静脉自控镇痛控制疼痛作用研究^*

hydromorphone and nalbuphine combination for patient-controlled intravenous analgesia in patients with primary liver cancer undergoing laparoscopic hepatectomy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	胡勇军, 汪磊, 刘宁, 晏华军. 间歇性全入肝血流阻断与区域性入肝血流阻断腹腔镜肝切除术治疗原发性肝癌患者术后恢复研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 411-414.
[2]	邱云, 杨玫, 薛红红. TACE联合超声引导下微波消融治疗特殊部位原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 419-422.
[3]	刘慧敏, 刘晓利, 王欣惠, 杨志云, 江宇泳. 原发性肝癌患者外周血CD4+T、CD8+T、Tc17、Th17和Treg淋巴细胞的变化及其意义^*[J]. 实用肝脏病杂志, 2022, 25(2): 255-258.
[4]	王婵, 沈长清, 吴晓琼, 邓程伟, 谢文蕊. 表柔比星药物洗脱微球肝动脉化疗栓塞术治疗不可手术切除的原发性肝癌患者临床疗效和安全性分析[J]. 实用肝脏病杂志, 2022, 25(2): 259-262.
[5]	周颜, 李国平, 邓俊, 杨美蓉, 吴晓霞, 张英, 朱宏英, 陈卫. 射频消融术治疗原发性肝癌患者接受胸腺素α₁维持治疗临床价值探讨^*[J]. 实用肝脏病杂志, 2021, 24(6): 907-910.
[6]	彭光明, 葛尚, 井桂银. 自适应性统计迭代重建联合低管电压提高肝细胞癌患者肝脏CT三期增强扫描图像质量研究[J]. 实用肝脏病杂志, 2021, 24(5): 737-740.
[7]	陈维, 魏涛, 杨岚, 伍小敏. 原发性肝癌患者癌组织NLRP3炎性小体表达状况研究[J]. 实用肝脏病杂志, 2021, 24(4): 544-547.
[8]	刘永昌, 赵殿堂, 孙启峰, 张启文. 吲哚菁绿荧光导航和三维可视化腹腔镜精准手术治疗原发性肝癌患者应用研究^*[J]. 实用肝脏病杂志, 2021, 24(4): 561-564.
[9]	王群先, 王云川, 陈有英. 肝脏部分切除术患者不同时机七氟烷吸入麻醉应用效果分析[J]. 实用肝脏病杂志, 2021, 24(4): 597-599.
[10]	安西全, 李燕, 孟根才次克. 替诺福韦联合索拉非尼治疗乙型肝炎相关中晚期原发性肝癌患者临床观察[J]. 实用肝脏病杂志, 2021, 24(4): 600-602.
[11]	谢宁, 黄娟秀, 严柳媚, 廖小莉. 长期核苷(酸)类抗病毒治疗的乙型肝炎肝硬化患者肝癌发生相关因素研究[J]. 实用肝脏病杂志, 2021, 24(3): 423-426.
[12]	莫娟, 闫文, 徐绍强. ALPPS治疗巨大原发性肝癌患者近远期疗效研究[J]. 实用肝脏病杂志, 2021, 24(2): 252-255.
[13]	赵闯, 梁超, 董宝剑, 陈祖涛. 原发性肝癌患者接受TACE术时行右美托咪定联合吗啡麻醉临床应用价值分析[J]. 实用肝脏病杂志, 2021, 24(2): 260-263.
[14]	朱雅萍, 魏金聚, 王妍心, 马俊琦. 异丙酚持续静脉泵入麻醉对接受微波消融治疗的原发性肝癌患者血管内皮糖萼和脑代谢的影响[J]. 实用肝脏病杂志, 2021, 24(2): 292-293.
[15]	李晓燕, 胡和平. 加强肝癌内科队伍建设,重视肝癌内科规范化和个性化诊疗决策[J]. 实用肝脏病杂志, 2021, 24(1): 1-3.